Screening for cardiac amyloidosis in patients with tenosynovial red flags: A collaboration between family medicine and cardiology.

Cardiac amyloidosis ECG Light chain amyloidosis Transthyretin amyloidosis

Journal

International journal of cardiology
ISSN: 1874-1754
Titre abrégé: Int J Cardiol
Pays: Netherlands
ID NLM: 8200291

Informations de publication

Date de publication:
30 Apr 2024
Historique:
received: 21 03 2024
revised: 23 04 2024
accepted: 29 04 2024
medline: 3 5 2024
pubmed: 3 5 2024
entrez: 2 5 2024
Statut: aheadofprint

Résumé

Amyloid deposition in tenosynovial structures precedes cardiac involvement up to 20 years. Therefore, a cardiological screening in patients with a history of tenosynovial manifestations of cardiac amyloidosis (CA) could lead to an increased number of early diagnoses. Patients with tenosynovial manifestations of CA (carpal tunnel syndrome, atraumatic biceps tendon rupture, lumbar spinal stenosis) have been identified by general practitioners and evaluated in a Referral Center for CA. Patients with a high suspicion of CA underwent the CA diagnostic pathway. Among 50 General Practitioners (GP) contacted, 10 (20%) agreed to participate in the study for a total of 5615 patients ≥60 years. One hundred forty-five patients met the inclusion criteria, 2 of them already had a diagnosis of CA, and 57 agreed to undergo a cardiological evaluation (electrocardiography, echocardiography, NTproBNP assay). The median age was 73 [67-80] years and 31 (54%) were women. Eight patients were suggested to start the CA diagnostic pathway, five of them underwent a complete diagnostic evaluation for CA, three refused to complete the diagnostic exams and no new diagnoses were made. A screening program for CA in patients with tenosynovial manifestations identified by general practitioners is feasible, but may not yield a high rate of new diagnosis. In this study, we identified two patients who already had a diagnosis of CA, and among patients at high risk for CA, 37% refused to complete the diagnostic pathway. Increased awareness of CA among patients might increase participation and diagnostic yield in screening studies. Further validation of this protocol is needed to evaluate its diagnostic performance.

Sections du résumé

BACKGROUND BACKGROUND
Amyloid deposition in tenosynovial structures precedes cardiac involvement up to 20 years. Therefore, a cardiological screening in patients with a history of tenosynovial manifestations of cardiac amyloidosis (CA) could lead to an increased number of early diagnoses.
METHODS METHODS
Patients with tenosynovial manifestations of CA (carpal tunnel syndrome, atraumatic biceps tendon rupture, lumbar spinal stenosis) have been identified by general practitioners and evaluated in a Referral Center for CA. Patients with a high suspicion of CA underwent the CA diagnostic pathway.
RESULTS RESULTS
Among 50 General Practitioners (GP) contacted, 10 (20%) agreed to participate in the study for a total of 5615 patients ≥60 years. One hundred forty-five patients met the inclusion criteria, 2 of them already had a diagnosis of CA, and 57 agreed to undergo a cardiological evaluation (electrocardiography, echocardiography, NTproBNP assay). The median age was 73 [67-80] years and 31 (54%) were women. Eight patients were suggested to start the CA diagnostic pathway, five of them underwent a complete diagnostic evaluation for CA, three refused to complete the diagnostic exams and no new diagnoses were made.
CONCLUSION CONCLUSIONS
A screening program for CA in patients with tenosynovial manifestations identified by general practitioners is feasible, but may not yield a high rate of new diagnosis. In this study, we identified two patients who already had a diagnosis of CA, and among patients at high risk for CA, 37% refused to complete the diagnostic pathway. Increased awareness of CA among patients might increase participation and diagnostic yield in screening studies. Further validation of this protocol is needed to evaluate its diagnostic performance.

Identifiants

pubmed: 38697400
pii: S0167-5273(24)00736-8
doi: 10.1016/j.ijcard.2024.132114
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

132114

Informations de copyright

Copyright © 2024. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that there is no conflict of interest.

Auteurs

Valentina Andrei (V)

Cardiovascular Department, San Donato Hospital, Arezzo, Italy; Tuscan Regional Amyloidosis Centre, Careggi University Hospital, Florence, Italy.

Alessia Argirò (A)

Tuscan Regional Amyloidosis Centre, Careggi University Hospital, Florence, Italy. Electronic address: argiro.alessia@gmail.com.

Carlotta Mazzoni (C)

Tuscan Regional Amyloidosis Centre, Careggi University Hospital, Florence, Italy.

Gabriele Rossi (G)

Tuscan Regional Amyloidosis Centre, Careggi University Hospital, Florence, Italy.

Maurizio Pieroni (M)

Cardiovascular Department, San Donato Hospital, Arezzo, Italy.

Leonardo Bolognese (L)

Cardiovascular Department, San Donato Hospital, Arezzo, Italy.

Marco Allinovi (M)

Tuscan Regional Amyloidosis Centre, Careggi University Hospital, Florence, Italy.

Cristina Scaletti (C)

Tuscany Region Rare Disease Network, Tuscany Region, Florence, Italy.

Federico Perfetto (F)

Tuscan Regional Amyloidosis Centre, Careggi University Hospital, Florence, Italy.

Francesco Cappelli (F)

Tuscan Regional Amyloidosis Centre, Careggi University Hospital, Florence, Italy.

Classifications MeSH